# A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer

> **NCT05394285** · PHASE2 · COMPLETED · sponsor: **Henan Cancer Hospital** · enrollment: 60 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Hetrombopag

## Key facts

- **NCT ID:** NCT05394285
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-21
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-07-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394285, "A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Anti-tumor Treatment in Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05394285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*